The major objective of this proposal is to develop a more effective form of active specific immunization with a vaccine made from synthetic peptides loaded on to dendritic cells in the human melanoma model. We have shown that a peptide and antigen presenting cell-based vaccine can induce a peptide specific and autologous melanoma reactive cytolytic T lymphocyte (CTL) response in melanoma patients. We have observed that in vitro stimulation of PBL from the immunized patients led to the rapid generation of peptide specific CTL, the CTL activities, however, often precipitously declined after repeated stimulation with the development of a Th2 type response. There was preliminary evidence of apoptosis in the process. These suggest that in vivo expansion of antigen specific CTL might also be regulated by a Th2 type response or through activation induced cell death (AICD). Hence, the proposed study will examine the mechanism of the decline of the CTL response with particular reference to the role of the Th2 cells and the role of AICD. Further, we shall test the hypothesis that a more effective peptide/APC-based immunization can be achieved with a number of innovations to the approach (such as by using dendritic cells, higher peptide loading, a different format of immunization consisting of priming and boosters, pretreating with cyclophosphamide to block the Th2 response, and using the type 1 cytokine IL-12 to induce a Th1 response). The study will be carried out with a clinical trial that will include these new approaches coordinated with extensive laboratory evaluations of the biologic response to test whether or not a Th1 type response can be induced, CTL response can be amplified, and memory response can be generated. The trial will be carried out with a vaccine made of DC (cultured in GM-CSF and IL-4) loaded with the HLA-A1 or - A2 determined peptides encoded by the following genes: MAGE-1, MAGE- 3, MART-1/Melan A. Thus, melanoma patients, who are HLA-A1 or HLA-A2 positive and whose melanomas express the above genes, will be primed with the vaccine and then given several boosters with a single low but biologically active dose of Interleukin-12 and a single injection of cyclophosphamide 3 days before immunization. A skin test with the naked peptide will be done after each vaccination and extensive analyses of the host immune responses in the draining lymph nodes, in tumors, and in circulation will be performed to determine whether or not the new approach could induce a Th1 type response and amplify specific CTL response and activate memory response.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA061398-08
Application #
6172359
Study Section
Special Emphasis Panel (ZRG2-ET-1 (02))
Program Officer
Xie, Heng
Project Start
1993-09-01
Project End
2001-09-30
Budget Start
2000-07-01
Budget End
2001-06-30
Support Year
8
Fiscal Year
2000
Total Cost
$307,125
Indirect Cost
Name
University of Connecticut
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Farmington
State
CT
Country
United States
Zip Code
06030
Ray, Swagatam; Chhabra, Arvind; Mehrotra, Shikhar et al. (2009) Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma. Clin Dermatol 27:603-13
Chhabra, Arvind; Yang, Lili; Wang, Pin et al. (2008) CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model. J Immunol 181:1063-70
Chhabra, Arvind; Mehrotra, Shikhar; Chakraborty, Nitya G et al. (2006) Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor. Eur J Immunol 36:3167-74
Mehrotra, Shikhar; Chhabra, Arvind; Chattopadhyay, Subhasis et al. (2004) Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy. J Immunol 173:6017-24
Chakraborty, Nitya G; Chattopadhyay, Subhasis; Mehrotra, Shikhar et al. (2004) Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 65:794-802
Mehrotra, Shikhar; Chhabra, Arvind; Chakraborty, Abolokita et al. (2004) Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. Immunology 113:472-81
Mehrotra, Shikhar; Stevens, Robert; Zengou, Ryan et al. (2003) Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro. Cancer Res 63:5607-14
Chakraborty, A; Li, L; Chakraborty, N G et al. (2000) Stimulatory and inhibitory differentiation of human myeloid dendritic cells. Clin Immunol 94:88-98
Chakraborty, N G; Li, L; Sporn, J R et al. (1999) Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines. J Immunol 162:5576-83
Chakraborty, A; Li, L; Chakraborty, N G et al. (1999) Stimulatory and inhibitory maturation of human macrophage-derived dendritic cells. Pathobiology 67:282-6

Showing the most recent 10 out of 17 publications